Cargando…
Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma
OBJECTIVES: Metabolic tumor volume (MTV) on (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is a promising prognostic predictor in pancreatic ductal adenocarcinoma (PDAC). However, the optimal segmentation method and threshold value to determine MTV for PDAC ar...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994512/ https://www.ncbi.nlm.nih.gov/pubmed/33777807 http://dx.doi.org/10.3389/fonc.2021.646141 |
_version_ | 1783669766621233152 |
---|---|
author | Tatewaki, Yasuko Terao, Chiaki Maeda Ariake, Kyohei Saito, Ryoko Mutoh, Tatsushi Shimomura, Hideo Motoi, Fuyuhiko Mizuma, Masamichi Odagiri, Hayato Unno, Michiaki Taki, Yasuyuki |
author_facet | Tatewaki, Yasuko Terao, Chiaki Maeda Ariake, Kyohei Saito, Ryoko Mutoh, Tatsushi Shimomura, Hideo Motoi, Fuyuhiko Mizuma, Masamichi Odagiri, Hayato Unno, Michiaki Taki, Yasuyuki |
author_sort | Tatewaki, Yasuko |
collection | PubMed |
description | OBJECTIVES: Metabolic tumor volume (MTV) on (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is a promising prognostic predictor in pancreatic ductal adenocarcinoma (PDAC). However, the optimal segmentation method and threshold value to determine MTV for PDAC are still unclear. We explored the optimal method and threshold value for the prognostic value of MTV measured on pre-treatment (18)F-FDG-PET/CT. METHODS: Seventy-three patients with resected PDAC who underwent (18)F FDG-PET/CT before surgical resection were enrolled. MTV values of the tumor were measured on FDG-PET/CT by the two fixed-threshold methods using threshold values as 2.0, 2.5, 3.0, and 3.5 for the absolute method and 35%, 40%, 42%, 45%, and 50% for the relative method. Receiver operating characteristic curve analysis for prediction of 1-year survival rates was conducted for determining the optimal threshold values, and we selected the optimal method and threshold value considering area under the curve. The prognostic values of each FDG-PET/CT parameter for disease-specific survival and recurrence-free survival were assessed with Kaplan–Meier method and Cox proportional hazard models. RESULTS: In receiver operating characteristic curve analysis, MTV by the fixed-absolute threshold method based on a threshold value of 3.5 (MTV3.5) performed best in our study with area under the curve 0.724, sensitivity of 65%, and specificity of 75%. In univariate and multivariate analyses, MTV3.5 was significantly associated with disease-specific and recurrence-free survival. CONCLUSIONS: MTV3.5 by absolute threshold on pre-treatment FDG-PET/CT was the best independent prognostic predictor in resectable PDAC compared with other absolute threshold values and relative threshold values. |
format | Online Article Text |
id | pubmed-7994512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79945122021-03-27 Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma Tatewaki, Yasuko Terao, Chiaki Maeda Ariake, Kyohei Saito, Ryoko Mutoh, Tatsushi Shimomura, Hideo Motoi, Fuyuhiko Mizuma, Masamichi Odagiri, Hayato Unno, Michiaki Taki, Yasuyuki Front Oncol Oncology OBJECTIVES: Metabolic tumor volume (MTV) on (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is a promising prognostic predictor in pancreatic ductal adenocarcinoma (PDAC). However, the optimal segmentation method and threshold value to determine MTV for PDAC are still unclear. We explored the optimal method and threshold value for the prognostic value of MTV measured on pre-treatment (18)F-FDG-PET/CT. METHODS: Seventy-three patients with resected PDAC who underwent (18)F FDG-PET/CT before surgical resection were enrolled. MTV values of the tumor were measured on FDG-PET/CT by the two fixed-threshold methods using threshold values as 2.0, 2.5, 3.0, and 3.5 for the absolute method and 35%, 40%, 42%, 45%, and 50% for the relative method. Receiver operating characteristic curve analysis for prediction of 1-year survival rates was conducted for determining the optimal threshold values, and we selected the optimal method and threshold value considering area under the curve. The prognostic values of each FDG-PET/CT parameter for disease-specific survival and recurrence-free survival were assessed with Kaplan–Meier method and Cox proportional hazard models. RESULTS: In receiver operating characteristic curve analysis, MTV by the fixed-absolute threshold method based on a threshold value of 3.5 (MTV3.5) performed best in our study with area under the curve 0.724, sensitivity of 65%, and specificity of 75%. In univariate and multivariate analyses, MTV3.5 was significantly associated with disease-specific and recurrence-free survival. CONCLUSIONS: MTV3.5 by absolute threshold on pre-treatment FDG-PET/CT was the best independent prognostic predictor in resectable PDAC compared with other absolute threshold values and relative threshold values. Frontiers Media S.A. 2021-03-12 /pmc/articles/PMC7994512/ /pubmed/33777807 http://dx.doi.org/10.3389/fonc.2021.646141 Text en Copyright © 2021 Tatewaki, Terao, Ariake, Saito, Mutoh, Shimomura, Motoi, Mizuma, Odagiri, Unno and Taki http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Tatewaki, Yasuko Terao, Chiaki Maeda Ariake, Kyohei Saito, Ryoko Mutoh, Tatsushi Shimomura, Hideo Motoi, Fuyuhiko Mizuma, Masamichi Odagiri, Hayato Unno, Michiaki Taki, Yasuyuki Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma |
title | Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma |
title_full | Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma |
title_fullStr | Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed | Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma |
title_short | Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative (18)F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Pancreatic Ductal Adenocarcinoma |
title_sort | defining the optimal method for measuring metabolic tumor volume on preoperative (18)f-fluorodeoxyglucose-positron emission tomography/computed tomography as a prognostic predictor in patients with pancreatic ductal adenocarcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994512/ https://www.ncbi.nlm.nih.gov/pubmed/33777807 http://dx.doi.org/10.3389/fonc.2021.646141 |
work_keys_str_mv | AT tatewakiyasuko definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma AT teraochiakimaeda definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma AT ariakekyohei definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma AT saitoryoko definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma AT mutohtatsushi definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma AT shimomurahideo definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma AT motoifuyuhiko definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma AT mizumamasamichi definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma AT odagirihayato definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma AT unnomichiaki definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma AT takiyasuyuki definingtheoptimalmethodformeasuringmetabolictumorvolumeonpreoperative18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyasaprognosticpredictorinpatientswithpancreaticductaladenocarcinoma |